Deerfield Management Company, L.P. (Series C) Foghorn Therapeutics Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,027,886 shares of FHTX stock, worth $15.2 Million. This represents 0.52% of its overall portfolio holdings.
Number of Shares
3,027,886
Previous 2,518,500
20.23%
Holding current value
$15.2 Million
Previous $14.5 Million
94.66%
% of portfolio
0.52%
Previous 0.3%
Shares
4 transactions
Others Institutions Holding FHTX
# of Institutions
80Shares Held
33.3MCall Options Held
8.7KPut Options Held
2.4K-
Flagship Pioneering Inc. Cambridge, MA12.7MShares$63.6 Million20.03% of portfolio
-
Bvf Inc San Francisco, CA5.3MShares$26.6 Million1.57% of portfolio
-
Raymond James & Associates St Petersburg, FL2.3MShares$11.5 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.73MShares$8.69 Million0.0% of portfolio
-
Euclidean Capital LLC New York, NY1.57MShares$7.9 Million1.62% of portfolio
About Foghorn Therapeutics Inc.
- Ticker FHTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,637,400
- Market Cap $209M
- Description
- Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...